New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
19:03 EDTSYNSynthetic Biologics reiterates collaboration with Intrexon still in effect
Synthetic Biologics reiterated that the exclusive channel collaboration agreement dated August 6, 2012 between the company and Intrexon remains in effect. This agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:23 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
06:59 EDTSYNSynthetic Biologics to initiate clinical trials of SYN-004
Synthetic Biologics announced that its Investigational New Drug, or IND, application which was submitted to the FDA in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile, or C. difficile, infection, antibiotic-associated diarrhea, and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end. Synthetic Biologics has met each milestone for its C. difficile program leading up to the IND submission to the agency. Clinical drug manufacturing of SYN-004 under cGMP guidelines to support Synthetic Biologics' planned Phase 1 and 2 clinical trials was completed on time to support the IND submission and clinical trial initiation. Most recently, the U.S. Patent and Trademark Office issued a Notice of Allowance for the first composition of matter patent application directly pertaining to SYN-004 in the U.S., which carries a patent term to at least 2031.
November 14, 2014
06:57 EDTSYNSynthetic Biologics reports Q3 EPS (8c), consensus (5c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use